Oxidative status and the response to pegylated-interferon alpha2A plus ribavirin in chronic genotype 4 HCV hepatitis by Ahmed, Mohammed Mahmound et al.
EXCLI Journal 2013;12:605-615 – ISSN 1611-2156 
Received: April 29, 2013, accepted: June 13, 2013, published: July 02, 2013 
 
 
605 
Original article: 
OXIDATIVE STATUS AND THE RESPONSE TO PEGYLATED-
INTERFERON ALPHA2A PLUS RIBAVIRIN IN  
CHRONIC GENOTYPE 4 HCV HEPATITIS 
 
Mohammed Mahmound Ahmed1*, Omar M.E. Abdel-Salam2, Nadia A. Mohammed3, 
Dawoud Fakhry Habib3, Hewida Ez-eldin Gomaa4  
 
National Research Centre, El Buhouth St., Dokki, Cairo, Egypt  
1 Internal Medicine Department 
2 Toxicology and Narcotics Department 
3 Medical Biochemistry Department 
4 Clinical Pathology Department. Medical Research Division,  
National Research Centre, Cairo, Egypt 
* Corresponding author: Mohammed Mahmoud Ahmed, National Research Centre,  
El Buhouth St., Dokki, Cairo, Egypt, Postal Code: 12311, E-mail: drmohmah@yahoo.com 
 
ABSTRACT 
Oxidative stress may play a pathogenic role in chronic hepatitis C (CHC). The present study 
examined the oxidative status in plasma of patients with CHC who received pegylated inter-
feron and ribavirin therapy. The following groups were included: (1) sustained virological re-
sponse (28 patients), (2) null response (26 patients), (3) breakthrough (24 patients), (4) relapse 
(24 patients), (5) spontaneous cure (23 patients) and (6) twenty five normal subjects as a con-
trol group. Markers of oxidative stress including plasma malondialdehyde, nitric oxide, re-
duced glutathione, total antioxidant capacity and uric acid as well as serum ALT, AST, alka-
line phosphatase, total bilirubin, albumin, prothrombin time were studied. The study indicated 
significant decline in reduced glutathione and total antioxidant capacity and markedly elevat-
ed levels of malondialdehyde and nitric oxide in all groups compared with the controls. Null 
response group had the highest levels of malondialdehyde and nitric oxide. Nitric oxide was 
significantly higher in those with null response compared with all other groups and with con-
trol subjects. Uric acid was significantly higher in spontaneous cure group compared with all 
other groups and with the controls. We concluded that CHC patients had increased oxidative 
stress. The oxidative status in plasma of these patients was not changed by antiviral therapy. 
The study also showed an important contribution of nitric oxide in null response patients. 
High serum uric acid did not interfere with the response and/or did not predict the response to 
antiviral therapy.  
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INTRODUCTION 
Reactive oxygen species as well as reac-
tive nitrogen species are products of normal 
cellular metabolism. The increased produc-
tion of oxygen free radicals and nitric oxide 
occurs also during the respiratory burst of 
phagocytic cells which plays an essential 
role in bacterial killing and in regulating the 
process of acute inflammation (Horta et al., 
2012; Halliwell, 1982). Under physiologi-
cal conditions free radical generation is 
counter balanced by several mechanisms 
which aim to maintain the redox baklace in 
the cell. Cellular defenses against free radi-
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cals and reactive oxygen species include 
enzymatic and nonenzymatic mechanisms. 
The enzymatic defense consists mainly of 
catalase, reduced glutathione (GSH), gluta-
thione peroxidase, and superoxide dis-
mutase; the nonenzymatic antioxidant 
mechanisms include ascorbic acid, vitamin 
E and GSH (Halliwell and Gutteridge, 
1984). When these protective or counter 
mechanisms are overwhelmed by excessive 
generation of oxygen and nitrogen free rad-
icals, oxidative and/or nitrosative stress 
then ensues. In these conditions the in-
creased free radicals can damage cell struc-
tures including membrane lipids, proteins 
or DNA resulting in impaired cell function 
(Halliwell, 1996; Kannan 2006). Oxidative 
stress has been implicated in a number of 
human diseases such as liver disease, diabe-
tes mellitus, heart failure, as well as in neu-
rodegenerative disorders (Halliwell, 2009). 
Hepatitis C virus (HCV) infection is a 
leading cause of chronic hepatitis and cir-
rhosis wide-world. It is estimated that ap-
proximately 160-170 million people world-
wide are affected with chronic hepatitis C 
(CHC) (Lavanchy, 2011). Cirrhosis eventu-
ally develops in 30 – 40 % of individuals 
unless the virus is eradicated with antiviral 
therapy (Bruno and Facciotto, 2008; Davis 
et al., 2010). Chronic hepatitis C virus in-
fection is also is associated with the highest 
hepatocellular carcinoma (HCC) incidence 
in persons with cirrhosis (Fattovich et al., 
2004). Current standard treatment for 
chronic hepatitis C includes pegylated inter-
feron (IFN) alfa in combination with ribavi-
rin (McHutchison et al., 2009, Guo et al., 
2012). The aim is to attain sustained viro-
logical response (SVR). The effectiveness 
of IFN-ribavirin in treating patients depends 
on HCV genotype. Patients with genotypes 
2 and 3 experience the highest SVR rate, 
with rates in excess of 80 %. For genotype 
1 HCV-infected patients, only 40-46 % of 
patients will achieve SVR (Shepherd et al., 
2004; Lee et al., 2012). However, approxi-
mately 10 % of patients receiving INF-
ribavirin therapy will stop treatment and 
30 % of patients require dose reduction be-
cause of side effects (Lee et al., 2012; 
Druyts et al., 2013). 
Recently, the role of oxidative stress in 
liver diseases and especially in patients 
with HCV infection has received consider-
able interest (Quarato et al., 2013; Yen et 
al., 2012; El-Kannishy et al., 2012). Oxida-
tive stress is a common pathogenetic mech-
anism contributing to initiation and pro-
gression of hepatic damage in a variety of 
liver disorders such as alcoholic liver dis-
ease, chronic viral hepatitis, autoimmune 
liver diseases and non-alcoholic steatohepa-
titis (Medina and Moreno-Otero, 2005). 
During the progression of HCV infections, 
reactive oxygen species are generated, and 
these then induce significant DNA damage 
and the development of hepatocellular car-
cinoma (Tsukiyama-Kohara, 2012). Hence, 
knowledge on the effect of IFN-ribavirin 
therapy on the oxidative status of patients 
with HCV infection is of marked clinical 
significance. Moreover, drugs with poten-
tial antioxidant activity are likely to be of 
benefit in the treatment with patients with 
chronic HCV infection. In this context, the 
potential benefit of silymarin (extracted 
from the seeds of Silybum marianum or 
milk thistle) in the treatment of liver diseas-
es may also stem from scavenging of reac-
tive oxygen species (Saller et al., 2001). Si-
lymarin supplemenation to antiviral therapy 
improved oxidative stress (Pár et al., 2009) 
and supplementation with antioxidants such 
as vitamins E, C and zinc appear to improve 
the redox status in these patients (Farias et 
al., 2012).  
The aim of the present study was to as-
sess the antioxidant status in chronic hepati-
tis C patients who received antiviral therapy 
with pegylated interferon and ribavirin. 
 
MATERIALS AND METHODS 
Subjects 
150 subjects were chosen in this study. 
125 chronic hepatitis C (CHC) patients 
were included. They were recruited from 
the Hepatology clinics of the General 
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Health Insurance Authority Polyclinics, in 
their first follow up visit, about two months 
after determining their response to their in-
terferon therapy. Their combined interferon 
therapy was in the form of a fixed weekly 
dose of 160 μg of 20 kD linear pegylated 
interferon a-2a (Reiferon Retard) in combi-
nation with ribavirin in standard and adjust-
ed doses. Their therapy was in accordance 
with the national protocols for the treatment 
of CHC approved by the Ministry of Health 
in Egypt (Taha et al., 2010; Esmat and Ab-
del Fattah, 2009). Subjects were fully in-
formed and consented in advance about the 
nature of our study. Patients were divided 
into the following 4 groups according to 
their response to interferon therapy:  
(1) Sustained virological response (SVR) 
group (28 patients). SVR is defined as 
undetectable HCV-RNA in serum, even 
after 24 weeks withdrawal of standard 
combination therapy (Welker and 
Zeuzem, 2009). In Egypt (genotype 4) 
the duration of treatment in this group 
was 48 weeks. 
(2) Null response group (26 patients). No 
response is defined as < 2 log (10) re-
duction in HCV RNA after 12 weeks 
treatment (Chayama et al., 2012). 
(3) Breakthrough group (24 patients). The 
breakthrough response is defined when 
HCV RNA rebounds and becomes de-
tectable before treatment is completed 
(Sherman et al., 2007). 
(4) Relapse group (24 patients). virological 
relapse is defined if HCV RNA de-
creases and remains below the limit of 
detection during treatment but becomes 
detectable after cessation of treatment 
(Dieterich et al., 2009). 
Group 5 and 6 (who needed no treatment) 
were included as follows: 
(5) Spontaneous cure group (23 patients). 
Spontaneous HCV Resolution (Self-
limiting HCV infection). The patient 
had at least 3 negative HCV-RNA PCR, 
6 months apart with positive HCV-Ab 
done by ELISA on many occasions 
(Spada et al., 2004). 
(6) The control group. This group included 
25 age, sex and culture matched healthy 
volunteers with a normal medical histo-
ry, physical examinations, blood bio-
chemistry and negative for anti-HCV 
antibodies. 
 
Exclusion criteria 
Although many of the following criteria 
were excluded before enrollment in com-
bined interferon therapy, we re-evaluated 
our subjects clinically and biochemically 
and excluded from this study those with a 
history of antioxidant use a month preced-
ing the study, alcohol, smoking, other 
known cause of liver disease such as meta-
bolic diseases, or another co-infections. Al-
so subjects with other chronic diseases such 
as diabetes mellitus or coronary heart dis-
ease were excluded. 
 
Biochemical studies 
Liver function tests including alanine 
transaminase (ALT), aspartate transaminase 
(AST), alkaline phosphatase (ALP) and al-
bumin were assayed using Olympus auto 
analyser AU400 (Olympus Diagnostica, Ja-
pan). Lipid peroxidation was assayed by 
measuring the level of malondialdehyde 
(MDA) in plasma using the method of 
Ruiz-Larrea et al (1994). Reduced glutathi-
one (GSH) was determined in brain tissue 
by Ellman's method (Ellman, 1959). Nitric 
oxide in serum was measured as nitrite us-
ing Griess reagent, according to the method 
of Moshage et al. (1995). Antioxidant ca-
pacity was measured by the reaction of an-
tioxidants in the sample with a defined 
amount of exogenously provided hydrogen 
peroxide according to (Koracevic et al., 
2001) using commertially available kit (Bi-
odiagnostics, Egypt). Uric acid concentra-
tion was measured by the direct enzymatic 
method, in which uric acid was oxidized by 
uricase coupled with peroxidase (Fossati et 
al., 1980). 
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HCV antibodies determination  
The presence of HCV antibodies was 
determined by third-generation enzyme 
linked immunosorbent assay (ELISA; 
CTK-Bioteck-USA). 
 
Detection of HCV-RNA by Real Time PCR 
and HCV Genotyping 
Viral RNA was extracted from patient’s 
plasma using the QIAamp Viral RNA Kit 
(Qiagen Hilden, Germany, Cat no. 52904) 
according to the manufacturer's protocol. 
HCV RNA was detected by commercially 
available Toyobo RNA-direct real time 
PCR kit on SLAN Real Time PCR Detec-
tion System, LG Lifescience, Korea. The 
HCV genotype was defined by the reverse 
line probe assay (INNO-LIPA v.1.0, in-
nogenetics, Ghent, Belgium) according to 
the manufacturer’s instruction. 
 
Statistical analysis of data  
Data are expressed as mean ± S.E. Sta-
tistical significance of the difference was 
analyzed using one way-ANOVA and post-
hoc Duncan test for multiple group compar-
ison. P values of < 0.05 were considered 
statistically significant. 
 
RESULTS 
The demographic data of our subjects 
revealed no significant differences among 
the studied groups as regard age, sex and 
body mass index (Table 1). The number of 
the subjects and the HCV-RNA PCR status 
of each group were also shown in Table 1.  
 
Concerning the studied parameters of 
liver function tests, there were no signifi-
cant changes in the mean value of serum 
albumin levels among the different studied 
groups. The mean values of both ALT and 
AST exhibited significant increases in all 
patient groups when compared to that of the 
control group except for the SVR group 
which showed a non significant increase. 
Such mean values exhibited significant in-
creases in all patient groups when com-
pared to that of the SVR group. The null re-
sponse and the breakthrough groups 
showed the highest significant mean values 
of ALT and AST. The mean values of se-
rum bilirubin exhibited significant increases 
in all patient groups when compared to that 
of the control group. There were no signifi-
cant changes in the mean levels of serum 
bilirubin among the patients groups. The 
mean values of serum alkaline phosphatase 
showed significant increases in the break-
through and SVR groups and non signifi-
cant increase in the null response and re-
lapse groups when compared with the con-
trols. Although within the accepted range, 
the mean values of prothrombin time were 
significantly increased in all patient groups 
when compared to that of the control group. 
Among the patients, the mean values of 
prothrombin time were significantly in-
creased in all groups when compared to that 
of SVR group (Table 2). 
Table 1: Characteristics of the selected groups 
Group Number Age (Years) Sex (M/F) BMI HCV- RNA PCR
Null response 26 48.4 ± 5.47 22/4 26.3 ± 3.34 Positive 
Breakthrough 24 50.4 ± 3.1 21/3 27.1 ± 2.57 Positive 
Relapse 24 48.2 ± 9.71 21/3 28.1 ± 2.1 Positive 
SVR 28 50.3 ± 7.34 23/5 26.3 ± 3.17 Negative 
Spontaneous cure 23 50.4 ± 5.32 20/3 27.8 ± 2.62 Negative 
Control 25 50.19 ± 6.5 21/4 26.5 ± 6.61 - 
Statistics - NS NS NS - 
Results are mean values ± S.E 
BMI = Body mass index, F = Female, M = Male, SVR = Sustained virological cure; NS = Not significant 
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Table 2: Serum levels of liver function parameters among different groups 
Group Albumin (g/L) 
ALP 
(U/L) 
ALT 
(U/L) 
AST 
(U/L) 
Bilirubin 
(mg/dl) 
PT 
(second) 
Null response 4.05 ± 0.15 68.18 ± 4.99 44.59 ± 4.71*+ 39.18 ± 3.90*+ 0.76 ± 0.05* 13.62 ± 0.27*# 
Breakthrough 4.24 ± 0.09 78.45 ± 5.41*+ 51.18 ± 4.16*+ 40.73 ± 5.22*+ 0.76 ± 0.06* 13.94 ± 0.35*+# 
Relapse 4.34 ± 0.07 64.28 ± 3.30# 31.33 ± 2.82*+# 27.17 ± 2.32*+# 0.79 ± 0.05* 13.73 ± 0.24*+# 
SVR 4.35 ± 0.11 73.30 ± 2.81*+ 18.87 ± 1.91# 19.60 ± 1.51# 0.73 ± 0.06* 13.06 ± 0.19* 
Spontaneous 
cure 4.41 ± 0.08 57.60 ± 4.52
# 33.70 ± 3.29*+# 29.30 ± 2.99*+# 0.64 ± 0.11* 12.69 ± 0.31* 
Control 5.0 ± 0.25 60.0 ± 3.65 12.5 ± 0.87 14.0 ± 0.93 0.41 ± 0.02 12.0 ± 0.21 
Statistics NS *P <0.05 vs. 
Control. 
+P < 0.05 vs. 
Spont. cure 
group. 
#P < 0.05 vs. 
Breakth. group. 
*P < 0.05 vs. 
Control. 
+P < 0.05 vs. 
SVR group 
#P < 0.05 vs. 
Null response 
group & 
Breakth. group. 
*P < 0.05 vs. 
Control. 
+P < 0.05 vs. 
SVR group. 
#P < 0.05 vs. 
Null response 
group & 
Breakth. group. 
*P < 0.05 vs. 
Control 
*P < 0.05 vs. 
Control 
+P < 0.05 vs. 
SVR group 
#P < 0.05 vs. 
Spont. group. 
Results are mean values ± S.E, ALP = Alkaline phosphatase, ALT = Alanine aminotransferase,  
AST = Aspartate aminotransferase, NS = Not significant, PT = Prothrombin time, SVR = Sustained virological response 
 
 
As regard the studied oxidative stress 
markers, there were significant decreases in 
the mean values of both reduced glutathi-
one and total antioxidant capacity of all pa-
tients groups when compared with that of 
the control group. There were no significant 
differences in the mean reduced glutathione 
levels among the patients groups. The mean 
values of total antioxidant capacity were 
significantly lower in the relapse, SVR and 
spontaneous groups when compared with 
the null group. Both the mean values of 
malondialdehyde and nitric oxide showed 
significant increases in all patients groups 
when compared with that of the control 
group. There were no significant differ-
ences in the mean malondialdehyde levels 
among the patients groups. The mean levels 
of nitric oxide were significantly higher in 
the null response group compared with the 
means of all the other patients groups. The 
mean serum uric acid levels were signifi-
cantly higher in all patients groups except 
the null response group when compared 
with that of the control group. Those who 
developed spontaneous cure showed the 
highest significant mean uric acid value. 
Other patients groups exhibited no signifi-
cant change in the mean uric acid level 
among them (Table 3). 
 
DISCUSSION 
The present study indicated that our pa-
tients with chronic hepatitis C irrespective 
to their response to pegylated-interferon al-
pha2a plus ribavirin therapy have elevated 
levels of oxidative stress in their plasma.  
The free-radical oxidation of polyun-
saturated fatty acids in biological systems is 
known as lipid peroxidation. The detection 
and measurement of lipid peroxidation is 
the evidence most frequently cited to sup-
port the involvement of free-radical reac-
tions in disease process. Aldehydes such as 
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Table 3: Serum levels of oxidative stress markers among different groups 
Group GSH (µmol/L) 
MDA  
(µmol/L) 
NO 
(µmol/L) 
TAC 
(mmol/L) 
UA 
(mg/dl) 
Null Response 0.78 ± 0.07* 49.42 ± 2.38* 78.06 ± 3.74* 1.39 ± 0.06* 4.99 ± 0.16+ 
Breakthrough 0.74 ± 0.05* 45.45 ± 3.15* 55.69 ± 2.96*+ 1.28 ± 0.06* 5.34 ± 0.19*+ 
Relapse 0.64 ± 0.04* 48.06 ± 2.11* 53.04 ± 2.00*+ 1.17 ± 0.03*+ 5.21 ± 0.16*+ 
SVR 0.74 ± 0.05* 44.97 ± 1.52* 59.88 ± 3.10*+ 1.22 ± 0.04*+ 5.47 ± 0.18*+ 
Spontaneous 
cure 0.60 ± 0.04
* 47.50 ± 2.31* 51.14 ± 2.86*+ 1.20 ± 0.05*+ 6.61 ± 0.54* 
Control 1.91 ± 0.10 27.43 ± 1.63 20.71 ± 1.16+ 1.94 ± 0.08 4.21 ± 0.23+ 
Statistics *P < 0.05 vs. 
Control 
*P < 0.05 vs. 
Control 
*P < 0.05 vs. 
Control 
+ P < 0.05 vs. 
Null R. group 
*P < 0.05 vs. 
Control 
+P < 0.05 vs. 
Null R. group 
*P < 0.05 vs.  
Control 
+P < 0.05 vs. 
Spont. cure group 
Results are mean values ± S.E, GSH = Glutathione, MDA = Malondialdehyde, NO = Nitric oxide,  
SVR = Sustained virological response, TAC = Total Antioxidant Capacity, UA = Uric Acid 
 
 
malondialdehyde resulting from lipid pe-
roxidation can bind covalently to proteins, 
thereby altering their function which results 
in enzyme inhibition and alteration of the 
structure of cellular receptors and cellular 
damage (Gutteridge, 1995). This study re-
vealed increased malondialdehyde (MDA) 
in plasma of patients with chronic hepatitis 
C, suggesting increased free radical genera-
tion and lipid peroxidation. Nevertheless, 
there were no significant differences in the 
mean MDA level among different patient 
groups e.g., between those with null re-
sponse or relapse and patients with sus-
tained virological response. This finding 
might suggest that antiviral therapy had no 
effect on the level of oxidative stress in our 
patients. 
Our results also demonstrated decreased 
endogenous antioxidant mechanisms in 
chronic hepatitis C. Reduced glutathione 
(GSH) was markedly decreased in the plas-
ma of all the patients groups. Glutathione is 
a major antioxidant in tissues which partic-
ipates nonenzymatically and enzymatically 
in supporting cellular redox balance and in 
protecting against oxidative damage by re-
active oxygen species (Wang and Ballatori, 
1998). Normally, oxidized glutathione is ef-
ficiently reduced by glutathione reductase 
which maintains more than 98 % of intra-
cellular gluathione in the reduced, thiol 
form (Spina and Cohen, 1998).  
Moreover, the study showed significant 
decrease in total antioxidant capacity 
(TAC) in all patients groups with chronic 
hepatitis C compared to the control group. 
Surprisingly, TAC was relatively increased 
in patients who had null response compared 
with relapse or spontaneous cure groups. 
Recently assays of TAC have been widely 
used in biomedicine with the aim of having 
an indication of oxidative status in body 
fluids or tissues. It has been suggested that 
low TAC could be indicative of oxidative 
stress. Conversely, increasing TAC through 
intervention has been taken as an indication 
of improved overall antioxidant status in 
the body. These assays, however, do not 
appear to reflect the sum of activities of dif-
ferent antioxidant defense mechanisms e.g., 
antioxidant enzymes (superoxide dismuta-
ses, glutathione peroxidases, and catalases) 
and glutathione which are the major antiox-
idant defense in cells, tissues, and body flu-
ids or takes into account the contribution of 
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small molecules e.g., urate, ascorbate, and 
tocopherol to antioxidant defense (Young, 
2001). 
Nitric oxide (NO) is a short-living gase-
ous molecule and a biological mediator 
generated from L-arginine by NO synthase 
(NOS). Three isoforms of NOS have been 
identified; a constitutively expressed endo-
thelial NOS (eNOS or type 3 NOS), neu-
ronal NOS (nNOS or type 1 NOS) and an 
inducible NOS (iNOS or type 2 NOS). In 
the liver, constitutively generated nitric ox-
ide is released continuously by the vascular 
endothelium. Being a vasodilator molecule, 
a key function of NO in the liver relates to 
the regulation of sinusoidal blood flow and 
vascular tone by exerting a basal dilator 
tone on the vascular smooth muscle cells 
(Rockey and Shah, 2004). Nitric oxide thus 
helps to maintain the hepatic microcircula-
tion and endothelial integrity. The role of 
nitric oxide in liver disease and especially 
in patients with hepatitis C virus infection 
has been emphasized by several authors. In 
diseased human livers, there is diminished 
activity of eNOS (Sarela et al., 1999) and a 
significant increase in iNOS in the cirrhotic 
liver (McNaughton et al., 2002). High con-
centrations of nitric oxide are generated by 
the inducible form of the enzyme nitric ox-
ide synthase (iNOS) by activated macro-
phages during inflammatory states. This is a 
defense mechanism by which the body aims 
to eliminate infection. An excessively high 
level of nitric oxide that follows contributes 
to the inflammatory response and tissue 
damage and participates in the onset of sev-
eral hepatopathies. However, in the course 
of liver regeneration, iNOS is expressed at 
moderate levels and contributes to inhibit 
apoptosis and to favor progression in the 
cell cycle until the organ size and function 
are restored (Martin-Sanz et al., 2002). 
Lake-Bakaar et al. (2001) found widespread 
expression of iNOS in hepatocytes in 
chronic HCV liver disease, irrespective of 
histological disease severity. The authors 
suggested that nitric oxide may play a role 
in the local control of chronic viral infec-
tions at tissue level, but this is not reflected 
in serum levels. Nitric oxide, however, is 
increased in the serum of patients with 
chronic HCV hepatitis (Pata et al., 2003; 
Hokari et al., 2005; Ibrahim et al., 2010). In 
these subjects, nitric oxide levels appear to 
be related to the outcome of pegylated-IFN-
α 2a plus ribavirin treatment (Hokari et al., 
2005; Ibrahim et al., 2010). In chronic hep-
atitis C, responder patients in whom hepati-
tis C virus was eradicated had significantly 
higher nitric oxide than the non-responders, 
in whom the virus was not eradicated (Ho-
kari et al., 2005). This difference was seen 
as early as 2 weeks after the initiation of 
treatment (Hokari et al., 2005). Conversely, 
suppression of nitric oxide might be a 
mechanism by which pegylated arginine 
deiminase reduces HCV viral titers and im-
proves liver function in patients with chron-
ic hepatitis C virus infection (Izzo et al., 
2007). Still other researchers observed that 
nitric oxide levels negatively correlated 
with fibrosis scores in chronic hepatitis pa-
tients. Nitric oxide which may be a sup-
pressor molecule for fibrosing levels are in-
versely related to fibrotic process (Pata et 
al., 2003). The present observations indi-
cated increased nitric oxide in the serum of 
different groups including those with sus-
tained virological response or spontaneous 
cure. The highest level of nitric oxide was, 
however, observed in patients who exhibit-
ed null response to antiviral therapy. 
Recently there has been much interest in 
uric acid in relation to liver disease. In 
Chronic hepatitis C and in non alcoholic 
fatty liver disease patients, hyperuricaemia 
was independently associated with severity 
of steatosis (Petta et al., 2011, 2012). More-
over, serum uric acid level > or =5.8 mg/dl 
was predictive of poor response to HCV 
treatment with pegylated-interferon and 
ribavirin (Pellicano et al., 2008). In the pre-
sent study, subjects with sustained re-
sponse, breakthrough, relapse or even spon-
taneous cure had significantly higher levels 
of serum uric acid compared with controls. 
Uric acid was significantly higher in those 
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who developed spontaneous cure compared 
with all other groups and with control sub-
jects. Thus uric acid level in serum had no 
impact on the response to antiviral therapy 
in this study. Uric acid is recognized as a 
marker of oxidative stress whereas the pro-
duction of the uric acid includes enzyme 
xanthine oxidase which is involved in pro-
ducing of radical-oxygen species. On con-
trary to this, uric acid also acts is an "anti-
oxidant", a free radical scavenger and a 
chelator of transitional metal ions which are 
converted to poorly reactive forms (Pasalic 
et al., 2012). Uric acid is a natural antioxi-
dant, accounting for up to 60 % of the free 
radical scavenging activity in human blood 
(Ames et al., 1981). Uric acid forms stable 
co-ordination complexes with iron ions that 
inhibited Fe3+-catalysed ascorbate oxida-
tion as well as lipid peroxidation (Sharma et 
al., 2012). Uric acid also can scavenge per-
oxyl, hydroxyl and superoxide radicals and 
inhibit oxidative protein, DNA and lipids 
damage (Ames et al., 1981; Davies et al., 
1986). In healthy subjects, systemic admin-
istration of uric acid which raised serum 
urate concentration from was associated 
with increased serum antioxidant capacity 
and reduced oxidative stress during acute 
physical exercise (Diaz et al., 2011). 
In summary, the present findings sug-
gest an elevated levels of oxidative stress in 
the serum of patients with chronic hepatitis 
C infection. Both increased lipid peroxida-
tion and decreased endogenous antioxidant 
mechanisms were observed. Oxidative 
stress was not changed by antiviral therapy. 
Supplementation with antioxidants might 
thus be advisable in these patients. 
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